RIVAROXABAN DEXCEL 2.5 MG
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
RIVAROXABAN
Available from:
DEXCEL LTD, ISRAEL
ATC code:
B01AF01
Pharmaceutical form:
FILM COATED TABLETS
Composition:
RIVAROXABAN 2.5 MG
Administration route:
PER OS
Prescription type:
Required
Manufactured by:
MEDICHEM S.A., SPAIN
Therapeutic area:
RIVAROXABAN
Therapeutic indications:
Rivaroxaban Dexcel 2.5 mg, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Rivaroxaban Dexcel 2.5 mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.
Authorization date:
2023-05-03
